Iladac L Capsule PR is a pharmaceutical formulation combining Levosulpiride 75 mg and Ilaprazole 10 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and dyspepsia. Ilaprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, effectively reducing gastric acidity and promoting mucosal healing in acid-related conditions. The combination of these two agents provides a synergistic therapeutic effect, making Iladac L Capsule PR suitable for the treatment of gastroesophageal reflux disease (GERD), functional dyspepsia, peptic ulcer disease, and other acid-peptic disorders accompanied by motility disturbances. The prolonged-release formulation ensures sustained drug release, enhancing patient compliance and maintaining consistent plasma concentrations. Iladac L Capsule PR should be used under medical supervision, with caution in patients with known hypersensitivity to its components, and is contraindicated in those with gastrointestinal obstruction or perforation. Adverse effects may include headache, dizziness, and mild gastrointestinal disturbances. Regular monitoring is advised during prolonged therapy.